United States - English - NLM (National Library of Medicine)

delaval - hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb) - hydrochloric acid 0.22 kg in 1 l - an aid to prevent hoof rot and hairy heel warts.  reduces the use of copper sulfate. ayuda en la prevencion de verruga peluda y gabarro.  diminuye el uso de sulfato de cobre. use directions not for human use.  do not use at full strength.  dilute according to directions.  read and follow label instructions carefully.  consult a veterinarian for proper diagnosis of lameness before using this product.  for best results, use this product as a part of a complete hoof care program. hoofbath booster hfb50 is a footbath additive specially developed to enhance the efficacy of copper and zinc sulfate.  it allows for reduction of consumption of copper sulfate in half. footbath dilutions:  footbath dilutions are intended for use on 200 cows, after which it is recommended that the footbath solution be discarded and replaced with a fresh footbath solution. - mix thoroughly 1 quart hoofbath booster hfb50 with 12.5 pounds of copper sulfate (1/4 of a 50 pound bag).  dilute to 50 gallons. - if footbath capacity is unknown,

United States - English - NLM (National Library of Medicine)

boiron - hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb) - hives triggered by sun exposure* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb) - hives triggered by sun exposure* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb) - hives triggered by sun exposure* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb) - hives triggered by sun exposure* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb) - hives triggered by sun exposure* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - coumarin (unii: a4vz22k1wt) (coumarin - unii:a4vz22k1wt), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl), formic acid (unii: 0yiw783rg1) (formic acid - unii:0yiw783rg1), hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb), nerium oleander leaf (unii: 7kv510r6h6) (nerium oleander leaf - unii:7kv510r6h6), ptelea trifoliata bark (unii: 5kqr6ftt0d) (ptelea trifoliata bark - unii:5kqr6ftt0d), lactic acid, l- (unii: f9s9ffu82n) (lactic acid, l- - unii:f9s - coumarin 6 [hp_x] in 1 ml - temporary relief of symptoms related to improper levels of stomach acid, including heartburn, dyspepsia and bowel irregularity.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. temporary relief of symptoms related to improper levels of stomach acid, including heartburn, dyspepsia and bowel irregularity.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

par pharmaceutical - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1)   for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless th

United States - English - NLM (National Library of Medicine)

par pharmaceutical companies, inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5) ]. zoledronic acid injection is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.2) ] - creatinine clearance less than 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see warnings and precautions (5.3) ]. - known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see post-marketing experience (6.2) ]. pregnancy category d [see warnings and precautions

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - hydrochloric acid - solution for infusion - 5.47mg/1ml